Tryp Therapeutics (CSE: TRYP- OTCQB: TRYPF) CEO Greg McKee joined Steve Darling from Proactive to talk about his new role as Chairman and CEO. McKee talks about his background and what he sees moving forward for the company.
McKee telling Proactive about some of their drugs in the pipeline and how close they are to clinical trial stage. This include Psilocybin-for-Neuropsychiatric Disorders targeting chronic pain and eating disorders. We also get an update on razoxane with his designed for soft tissue sarcomas.